NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2022, Vol. 34 ›› Issue (2): 272-281. doi: 10.16333/j.1001-6880.2022.2.013

Previous Articles     Next Articles

Analysis on the difference of metabolites in xylem and phloem of Spatholobi Caulis

CHEN Fei1,MEI Yu-qi2,LIU Xun-hong2*   

  1. 1Rugao Hospital of Traditional Chinese Medicine,Rugao 226500,China; 2School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China
  • Online:2022-02-28 Published:2022-03-07

Abstract:

Based on ultra-fast performance liquid chromatography coupled with triple quadrupole-time of flight ion trap tandem mass spectrometry (UFLC-Triple TOF-MS/MS) technology,metabolites in the xylem and phloem of Spatholobi Caulis were analyzed.Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to screen potential differential compounds.Combined with network pharmacology analysis,the potential targets and pathways corresponding to differential components in xylem and phloem of Spatholobi Caulis were explored,and the “component-target-pathway” network was constructed.As a result,the samples can be effectively distinguished in the statistical model.Thirteen different components were preliminarily screened and identified,and the relative content of them in xylem was significantly higher than that in phloem.According to network pharmacology analysis,it was found that vestitol may be the key active component of Spatholobi Caulis and the four targets,PIK3R1,PIK3CA,MAP2K1,PIK3CB,may play a key role.The differential markers in Spatholobi Caulis mainly act on proteoglycan-acting cancer,cancer pathway and PI3K-Akt signaling pathway.This study provides basic information for revealing the influence of different tissue parts on the synthesis and accumulation of the metabolites of Spatholobi Caulis,and also provides a basis for further clarifying the material basis and main regulatory targets of it.

Key words: Spatholobi Caulis, tissue, metabolites, multivariate statistical analysis, network pharmacology 

CLC Number: